N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma

European Journal of Biochemistry

Volumn 269, Issue 15, 2002, Pages 3732-3741

  Hatzi, Elissavet ^a   Murphy, Carol ^a,b   Zoephel, Andreas ^c   Ahorn, Horst ^c   Tontsch, Ulrike ^c   Bamberger, Ana Maria ^d   Yamauchi Takihara, Keiko ^e   Schweigerer, Lothar ^f   Fotsis, Theodore ^a,g  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Endothelial cell; LIF; N myc; Neuroblastoma; STAT3

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; STAT3 PROTEIN;

ADENOVIRUS; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; DOWN REGULATION; ENDOTHELIUM CELL; GENE AMPLIFICATION; GENE EXPRESSION; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOVIRIDAE;

EID: 0036373101     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2002.03066.x     Document Type: Article

References (56)

1. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights
2. The N-myc oncoprotein is associated in vivo with the phosphoprotein Max (p20/22) in human neuroblastoma cells
3. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells
4. N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization
5. Defective development of the embryonic liver in N-myc-deficient mice
6. Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus
7. Regulation of the neural crest cell fate by N-myc: Promotion of ventral migration and neuronal differentiation
8. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma
9. Targeted expression of MYCN causes neuroblastoma in transgenic mice
10. Amplification of MYCN in untreated human neuroblastomas correlates with advanced disease stage
11. Detection of NMYC oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: Relationship to clinical outcome
12. Embryonic lethality resulting from disruption of both N-myc alleles in mouse zygotes
13. The N-myc proto-oncogene: Developmental expression and in vivo site-directed mutagenesis
14. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma
15. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: Evidence for induction of autocrine growth activity
16. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
17. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
18. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
19. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
20. How tumors become angiogenic
21. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells
22. Cleavage of structural proteins during the assembly of the head of bacteriophage Tu
23. The N-myc oncogene in human neuroblastoma cells: Down-regulation of an angiogenesis inhibitor identified as activin A
24. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis
25. Localization of regulatory elements controlling human MYCN expression
26. Transcriptional regulation of the human 'leukemia inhibitory factor' gene: Modulation by gluco-corticoids and estradiol
27. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes
28. Myc target genes
29. Direct recruitment of N-myc to target gene promoters
30. Identification of c-myc responsive genes using rat cDNA microarray
31. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc
32. Myc and Max function as a nucleoprotein complex
33. Methylation-sensitive sequence-specific DNA binding by the c-myc basic region
34. Sequence-specific DNA binding by Myc proteins
35. c-myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II
36. C-myc: Evidence for multiple regulatory functions
37. A link between c-myc-mediated transcriptional repression and neoplastic transformation
38. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F onco-proteins
39. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: Characterization of an Ada complex and the SAGA (Spt/Ada) complex
40. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130
41. A novel function for Myc: Inhibition of C/EBP-dependent gene activation
42. C-myc transrepression and cell transformation
43. Identification of downstream-initiated c-myc proteins which are dominant-negative inhibitors of transactivation by full-length c-myc proteins
44. Transactivation-defective c-mycS retains the ability to regulate proliferation and apoptosis
45. Interleukin-18 acts as an angiogenesis and tumor suppressor
46. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: Identification as leukemia inhibitory factor
47. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro
48. Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo
49. Stat3 activation is required for cellular transformation by v-src
50. Transcriptional activation of the p21 (WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells
51. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1
52. bFGF and LIF signaling activates STAT3 in proliferating myoblasts
53. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells
54. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: Mutant Tie-2 causing venous malformations signals a distinct STAT activation response
55. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300
56. Suppression of head formation by Xmsx-1 through the inhibition of intracellular nodal signaling